Biosimilars were ‘plan B,’ says portfolio pumped Merck KGaA
Germany's Merck has confirmed it is divesting its biosimilars division in order to concentrate on its innovative product pipeline.
Archives for March 10, 2017
Horizon inks optimisation tech deal for next generation CHO K1 cell line
Horizon Discovery Group has teamed up with Amplycell to optimise its GS (glutamine synthetase) null CHO K1 cell line.